Literature DB >> 17000284

Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors.

K Robert Shen1, Stephen D Cassivi, Claude Deschamps, Mark S Allen, Francis C Nichols, W Scott Harmsen, Peter C Pairolero.   

Abstract

OBJECTIVE: A paucity of outcome data exists regarding patients with proximal stomach cancer involving the distal esophagus (Siewert type III tumors). This is especially true with regard to long-term survival rates after surgical intervention.
METHODS: Medical records were reviewed of all patients who underwent total gastrectomy and distal esophagectomy with Roux-en-Y esophagojejunostomy for Siewert type III tumors from January 1975 through December 2000.
RESULTS: There were 116 patients (93 men and 23 women). The median age was 66 years (range, 22-87 years). Pathologic stage was 0 (carcinoma in situ) in 1 patient, IB in 13 patients, II in 17 patients, IIIA in 34 patients, IIIB in 10 patients, and IV in 41 patients. Complete resection was achieved in 69 (59.5%) patients. Eleven (9.5%) patients were treated with neoadjuvant therapy, 49 (42.2%) received adjuvant therapy, and 6 (5.2%) received intraoperative radiation. Follow-up was complete in 114 (98.3%) patients, ranging from 1 to 281 months (median, 14 months). Operative mortality was 5.2%. Complications occurred in 51 (43.9%) patients. Clinically significant anastomotic leaks occurred in 15 (12.9%) patients. Median hospitalization was 13 days (range, 8-70 days). Median follow-up was 14 months (range, 1-281 months). Overall median survival was 434 days, with 1-, 5-, and 10-year survivals of 56.2%, 19.0%, and 13.5%, respectively. The only factor associated with increased hospital mortality was anastomotic leakage (P = .002). Incomplete resection, increased tumor stage and grade, and splenic involvement significantly worsened long-term survival.
CONCLUSIONS: Total gastrectomy and distal esophagectomy for Siewert type III tumors is associated with reasonable mortality and significant morbidity. Although often palliative, surgical intervention can provide long-term survival, especially in patients with completely resected, early-stage, low-grade tumors.

Entities:  

Mesh:

Year:  2006        PMID: 17000284     DOI: 10.1016/j.jtcvs.2006.05.064

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Should Pyloric Lymph Nodes Be Dissected for Siewert Type II and III Adenocarcinoma of the Esophagogastric Junctions: Experience from a High-Volume Center in China.

Authors:  Huihua Cao; Marie Ooi; Zhan Yu; Qing Wang; Zhong Li; Qicheng Lu; Yugang Wu
Journal:  J Gastrointest Surg       Date:  2018-10-17       Impact factor: 3.452

2.  The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients.

Authors:  Hironobu Goto; Masanori Tokunaga; Yuichiro Miki; Rie Makuuchi; Norihiko Sugisawa; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masahiro Niihara; Yasuhiro Tsubosa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2014-03-22       Impact factor: 7.370

3.  "A hybrid approach for GISTs near the esophagogastric junction, a case report".

Authors:  William G Aguayo; Christian L Rojas; Gabriel A Molina; B Andrés Cárdenas; Emilio F Parreño; Sergio D Melendez; Monica P Alvarez; Veronica M Basantes; Johan J Aguayo; Fatima V Gualotuña
Journal:  Ann Med Surg (Lond)       Date:  2021-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.